This study looks at how a medicine called **dupilumab** can help prevent lung problems getting worse in people with serious asthma. Asthma is when it's hard to breathe because the airways in the lungs get swollen or narrow. Dupilumab is a medicine that helps reduce this swelling.
The study will take about **3 years** with some extra check-ups at the end. Participants will be randomly assigned to two groups. One group gets dupilumab, the other gets regular asthma treatment. Neither the patients nor the doctors will know who gets which treatment, which is called a **double-blind** study. To be part of this study, you need to be **18 or older** and have asthma that isn’t well controlled with regular medicine.
Key Points:- This study lasts for about 3 years, plus some follow-up time.
- Participants will need to come for regular visits for check-ups.
- The study will compare dupilumab with standard asthma care.
How understandable was the trial content above?
Hard to understand
Easy to understand